Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer
This is a Phase I study. The purpose of this study is to determine what is the best dose of the study drug BYL719 in combination with the study drug LJM716 and traztuzumab (Herceptin®). The study will test the safety of the combination of these three drugs, and to find out the effects, good and/or bad, that these three drugs have on the patient and breast cancer.
Breast Cancer
DRUG: BYL719|DRUG: LJM716|DRUG: TRASTUZUMAB
maximum tolerated dose (MTD) of BYL719, 1 year|recommended dose for expansion (RDE), The MTD is defined as per the Continual Reassessment Method. The RDE will be determined by the Principal Investigator with input from other investigators and Novartis, and will be based on the MTD, review of required intra-patient dose de-escalations, pharmacodynamic evaluations, and consideration of toxicities occurring in cycles 2+., 1 year
Toxicity will be assessed using the NCI Common Toxicity Criteria, version 4.0, unless otherwise specified. The type, severity, timing and relationship of each adverse event will be documented., 2 years
This is a Phase I study. The purpose of this study is to determine what is the best dose of the study drug BYL719 in combination with the study drug LJM716 and traztuzumab (Herceptin®). The study will test the safety of the combination of these three drugs, and to find out the effects, good and/or bad, that these three drugs have on the patient and breast cancer.